If you have depression and treatment has not worked the way you hoped, you are in a large group. Only about 6 in 10 US adults who have a major depressive episode in a given year get any treatment for it. And research on mood disorders as a group found a median delay of 6 to 8 years between the first symptoms and the first conversation with a professional. That is a long time to carry something this heavy. The good news is that depression research is in its most active stretch in decades. This article covers what is approved right now, what researchers are testing, and why some of it takes so long.
Looking for treatment options for Depression?
Browse open Depression Clinical trials near you! We'll handle the follow-up.
What is approved today
Depression actually has more approved medicines than most conditions. More than 30 antidepressants have FDA approval, spread across several classes with names like SSRIs, SNRIs, and tricyclics. In plain terms, they all work on chemical messengers in the brain, each class in its own way. Most of them came out of the same general playbook, which is why for a long time new antidepressants felt like variations on a theme. That started to change in recent years. A few approvals worth knowing about:
Spravato (esketamine). A nasal spray related to ketamine, approved in 2019 for treatment resistant depression, taken together with an oral antidepressant. In January 2025 the FDA approved it as the first medicine that can be used on its own for treatment resistant depression, without another antidepressant alongside it.
Auvelity (dextromethorphan and bupropion). A combination pill approved in 2022 for major depressive disorder. It works on a different brain target than classic antidepressants.
Zurzuvae (zuranolone). Approved in August 2023 as the first pill for postpartum depression. Before it, the only medicine approved specifically for postpartum depression was Zulresso (brexanolone, 2019), which is given by IV infusion in a medical setting.
Exxua (gepirone). Approved in 2023 for major depressive disorder.
And it is not only pills. TMS, which uses magnetic pulses on the outside of the head, has been FDA cleared for depression since 2008. Vagus nerve stimulation is approved for treatment resistant depression. ECT remains an option for severe cases. Talk therapy is a core treatment too, and as you will see below, a large share of today's studies test therapy programs and other non drug approaches.
One thing to keep in mind: naming these medicines here is not a recommendation. Which treatment fits you, if any, is a conversation for you and your doctor.
What researchers are studying now
As of August 2026, more than 1,400 depression studies are recruiting participants on AllClinicalTrials.com. A few storylines stand out.
Psilocybin has passed its biggest test yet. Compass Pathways runs the largest psilocybin program for treatment resistant depression. In June 2025, its first big trial worked: six weeks after one 25 mg dose, people who got psilocybin felt noticeably better than people who got a placebo. In February 2026, a second big trial worked too. That makes this drug, called COMP360, the first psychedelic to pass two major trials for treatment resistant depression. It is not approved yet, and approval is never guaranteed, but no psychedelic has ever gotten this close before.
A new drug aims at a specific problem: depression plus insomnia. Johnson & Johnson's seltorexant is built for people who have both. In its main trial, announced in 2024, it helped with both the depression and the sleep problems more than a placebo did when added to an antidepressant. The company plans to seek approval. What makes this different is the idea behind it: instead of treating depression as one single thing, it targets one specific pattern within it.
Researchers are also trying to match treatment to the person, not just the diagnosis. Some are using brain scans like EEG to predict who will respond to which treatment. Others are studying medicines already in use to understand them better. At Mount Sinai, a study of 120 people is looking at what ketamine actually does inside the brain, not just whether it helps. That matters because if doctors know exactly what a medicine changes in the brain, they can start guessing who it will help before they even try it, instead of testing one antidepressant after another and waiting weeks each time.
Fast acting medicines are their own growing area. Regular antidepressants usually take weeks to work. Newer options, including the drug class Zurzuvae belongs to and ketamine related medicines, work much faster, which is why researchers are so interested in them.
Here's something that surprises people: most depression studies are not testing a drug at all. Most of what's recruiting right now looks at therapy programs, devices, brain imaging, and apps, run mostly by universities and hospitals like Massachusetts General, Yale, and NYU Langone. So joining a study often does not mean taking an experimental medicine. One good example on our own platform: Stanford is enrolling 240 people with mild to moderate depression in a study pairing brain based feedback with a phone app, no drug involved at all.
This also explains who is doing the research. Drug company trials are a small part of what's recruiting. Most of the work comes from universities, hospitals, and public funding, which means smaller studies asking narrower questions, and slower progress toward any single approval.
Why depression research takes time
New depression treatments move slower than patients would like. There are real reasons for it.
The placebo problem. In a typical antidepressant trial, roughly 4 in 10 people improve on placebo. That is a good thing for those participants, but it makes it hard to tell whether a new medicine adds anything. A real effect has to show up clearly above that noise, so trials need to be large and careful. It also means a treatment can genuinely help people and still fail its trial, simply because the placebo group improved almost as much.
The measurement problem. There is no blood test or scan that measures depression. Studies rely on symptom scales, where a clinician scores your symptoms in a structured interview, usually comparing your score at the start with your score around week 6 or 8. "Response" typically means your score dropped by at least half. It works, but it is slower and fuzzier than measuring, say, blood pressure. Two people with the same score can also be living quite different lives, one barely sleeping, the other sleeping all day, and the number does not capture that.
The blinding problem. Trials work best when nobody knows who got the real drug. With ketamine related medicines and psychedelics, participants can often tell. Researchers are still working out how to design fair tests around that.
The representation problem. Racial and ethnic minorities and older adults have historically been underrepresented in antidepressant trials. That means the evidence base fits some patients better than others, and it is a reason many studies now actively look for participants from underrepresented communities.
Depression affects more than mood
Depression rarely travels alone. It commonly occurs alongside anxiety and substance use disorders, like AUD or OUD, and it is frequent in people with chronic physical illnesses like heart disease, diabetes, cancer, and Parkinson's disease. And the relationship runs both ways, because depression can make the outcomes of those conditions worse.
You can see that two way link in the research itself. Some studies recruit people specifically because they have both conditions at once, on the logic that depression in the middle of another illness may need its own answers rather than a copy of the general playbook.
The stakes show up in population data too. A large 2025 meta-analysis in World Psychiatry found that people with depression have roughly twice the overall death rate of the general population, and deaths from physical illnesses were about 1.6 times more common. These are population level numbers, not predictions about any one person. They say nothing about your own future. What they do say is that treating depression, and building better treatments, genuinely matters.
What is situational depression?
You will see this phrase a lot, and it is worth knowing that doctors call it something else. Situational depression is the everyday name for adjustment disorder with depressed mood. It starts within about three months of a stressful life event, a job loss, a divorce, a move, a diagnosis, and it brings sadness, hopelessness, crying, and a loss of joy in things you used to enjoy. The timing is what separates it from major depression: it is tied to an identifiable event, and it usually eases as you adjust to the new situation. That does not make it trivial, and it does not mean you should wait it out alone if it is not lifting.
What is high functioning depression?
Another phrase you will run into that is not a formal diagnosis. High functioning depression, sometimes called functional depression, usually describes someone who is depressed and still getting through work, family and daily obligations. From the outside nothing looks wrong, which is exactly why it goes unnoticed for years. The closest medical term is persistent depressive disorder, a milder but longer lasting form of depression whose symptoms usually run at least two years. Managing to function is not the same as being well, and it does not disqualify anyone from treatment or from a study.
Common myths
"Depression is just a chemical imbalance."
This one is everywhere, and it is outdated. Research shows depression comes from a mix of genetic, biological, environmental, and psychological factors. Modern studies focus on brain circuits, neuroplasticity, stress hormones, and even inflammation, not one missing chemical.
"Depression is weakness, or just sadness."
It is a medical condition, not a character trait. Sadness passes on its own. Depression lasts for weeks or longer and interferes with work, relationships, and basic daily life, and it responds to treatment the way medical conditions do.
"Nothing new has happened in depression treatment for decades."
Understandable, but no longer true. The first nasal spray for treatment resistant depression, the first pill for postpartum depression, and the first psychedelic to pass two Phase 3 trials all arrived within the last seven years.
"If it runs in your family, you are going to get it."
Genes matter, but they are not a verdict. In a large analysis of twin studies, genes explained about 37 percent of the risk of major depression. A parent or sibling with depression raises your own risk roughly two to three times. That is real, and it is also far from certain: many people with depression have no family history at all, and many relatives of people with depression never develop it.
"Men do not really get depressed."
They do, and it often looks different. Instead of sadness it can show up as anger or irritability. Men are also less likely to recognize it, talk about it, or ask for help, which is why depression in men is more often missed and left untreated.
From mild symptoms to treatment resistant depression
Depression doesn't have official stages the way some diseases do. Doctors just describe it as mild, moderate, or severe, based on how many symptoms you have and how much they get in the way of your life. Studies use the same idea. Some look for people with mild or moderate symptoms, others look specifically for depression that has stuck around a long time or is severe.
What care usually looks like changes along that range. This is just a general picture of common practice, not advice for your own situation.
Mild. Talk therapy is often the first step, sometimes along with changes to sleep, activity, and support. Medication may or may not be part of it. Studies at this level often test therapy programs, apps, and devices instead of drugs, which is why joining one here rarely means taking an experimental medicine.
Moderate. Medication and therapy are usually used together. This is often where the trial and error people talk about begins, since it can take weeks to know if a medicine is working.
Severe. Care is more intensive and closely watched, and options like ECT can come up. Studies at this level are usually smaller and run at specialist centers.
Treatment resistant depression is its own category in research. Doctors use this term when depression hasn't gotten better even after standard antidepressant treatment. It's common, and it's where a lot of the newest research is focused, including esketamine, psilocybin, and device based treatments. Some studies aren't testing new treatments at all, they're trying to understand why the current ones stop working. Unity Health Toronto is looking for 45 people for a study on brain chemistry in treatment resistant depression. And at the more severe end, the University of Minnesota is running a small 15 person study for people with severe treatment resistant depression, the kind of study that only makes sense once everything else has already been tried. If this sounds like your situation, our article on what to do when depression medication isn't enough goes deeper.
How to find a depression study
You can browse recruiting depression studies on AllClinicalTrials.com by condition and location, whether that's a 4 week digital program at Auburn University for people with moderate depression, or a larger drug trial testing a treatment for depression with daytime sleepiness. Applying takes about 5 minutes. After that, the study team checks if you match the study's criteria, usually with a short set of questions about your symptoms and treatment history. If you're a fit, they walk you through informed consent, where every procedure, risk, and detail about compensation gets explained before you agree to anything. You can say no at any point, even after you've started.
Common questions
What is depression, in simple terms? Depression is a medical condition. Your mood drops, things you normally enjoy stop feeling like anything, and your energy goes. That state holds for weeks and starts getting in the way of ordinary life. It is not the same as a bad stretch that passes on its own, and it is not a matter of willpower. Most people see it appear for the first time somewhere between their late teens and their mid 20s, though it can begin at any age.
Is psilocybin approved for depression? No. COMP360 psilocybin has now met its main goal in two Phase 3 trials for treatment resistant depression, which is the furthest any psychedelic has gotten, but as of August 2026 it is not FDA approved. It is only available inside clinical trials.
How do studies measure whether depression improved? With clinician rated symptom scales, most often the MADRS or the HAM-D. Trials usually compare scores at the start with scores around week 6 or 8, and a drop of half or more counts as a response.
Are there depression studies that don't involve medication? Yes, most of them. The majority of recruiting depression studies test things like therapy programs, brain stimulation devices, imaging, and digital tools rather than experimental drugs.
What is unipolar depression? It is another name for major depression, the most common form. "Unipolar" means the mood moves in one direction only, down. That is the contrast with bipolar disorder, where depressive episodes alternate with manic ones. In study listings the same thing is usually written as major depressive disorder, or MDD.
See depression clinical trials recruiting now.
More than a thousand depression studies are looking for participants. Browse depression clinical trials and apply in about 5 minutes.